Marine Gogia | Medicine | Best Researcher Award

Dr. Marine Gogia | Medicine | Best Researcher Award

Program Director at Georgian Harm Reduction Network, Georgia.

Dr. Marine Gogia is a distinguished Public Health Specialist and Patient Advocate with extensive experience in harm reduction and epidemiology. She is currently pursuing a Ph.D. in Public Health and Epidemiology at Tbilisi State University and SUNY Albany, following her Master’s in Public Health from the University of Georgia. Dr. Gogia’s career highlights include her role as Programs Director at the Georgian Harm Reduction Network, where she manages significant projects like the Global Fund initiative targeting HIV/AIDS prevention and harm reduction. Her research encompasses HIV self-testing, hepatitis C treatment, and risk behavior assessments among marginalized groups. Dr. Gogia’s contributions extend to her leadership roles with the European AIDS Treatment Group and various international health organizations. She has been recognized for her impactful research and advocacy, which include numerous publications and presentations at global conferences.

Profile
Education

Dr. Marine Gogia is a highly educated public health specialist with a strong academic background. She is currently pursuing a Ph.D. in Public Health and Epidemiology at Tbilisi State University and SUNY Albany, USA (2022-2025). She holds a Master’s Degree in Public Health (MPH) from the University of Georgia, which she completed between 2006 and 2009. Dr. Gogia’s foundational education was at Tbilisi State Medical University, where she studied Preventive Medicine (1996-2002). Her commitment to continuing education is evident from her participation in specialized courses, including the European Patients Academy (EUPATI) Expert Patients Course (2017-2018) and the EATG Training Academy’s STEP-UP program (2014-2015). This extensive educational background has equipped her with a robust understanding of public health, epidemiology, and the skills necessary to address complex health challenges effectively.

Professional Experience

Dr. Marine Gogia, a distinguished Public Health Specialist and Patient Advocate, has amassed extensive experience in public health, harm reduction, and infectious disease control. Currently a Programs Director at the Georgian Harm Reduction Network (GHRN), she leads critical projects such as the Global Fund initiative to prevent HIV/AIDS and minimize drug-related harm. Her role encompasses both management and research, with notable studies on HIV self-testing and Hepatitis C elimination. Dr. Gogia has also contributed as a Co-chair at the European AIDS Treatment Group (EATG), where she provides technical expertise and strategic direction. Her prior roles include consulting for WHO and the Global Fund, and serving as a Program Coordinator at Curatio International Foundation. Her work reflects a commitment to improving health outcomes and advocating for marginalized communities through rigorous research and strategic program implementation.

Research Interest

Dr. Marine Gogia’s research interests center around public health, with a particular focus on HIV/AIDS, harm reduction, and epidemiology. She is dedicated to advancing strategies for combating HIV and hepatitis C, especially among vulnerable populations such as people who inject drugs (PWID) and marginalized groups. Her work involves evaluating and improving harm reduction programs, assessing risky behaviors, and enhancing access to healthcare services through innovative research methodologies like simplified bio-behavioral surveillance surveys. Dr. Gogia is also actively involved in policy advocacy and capacity building, contributing to global health guidelines and strategies. Her research aims to bridge gaps in healthcare access and improve the effectiveness of public health interventions, with significant contributions to regional and international efforts in infectious disease control and prevention.

Research Skills

Dr. Marine Gogia possesses exceptional research skills demonstrated through her extensive experience in public health and epidemiology. Her expertise includes conducting bio-behavioral surveillance surveys, operational research, and evaluating HIV and hepatitis C testing and treatment programs. Dr. Gogia excels in designing and implementing research methodologies, such as the BSS-Lite survey, to assess risky behaviors among people who inject drugs (PWIDs). She is adept at analyzing data related to HIV self-testing acceptability and identifying barriers to HCV program enrollment. Her research skills are further evident in her contributions to studies on legal and regulatory barriers, and her ability to synthesize complex information into actionable insights for policy-making. Dr. Gogia’s proficiency extends to training and consultancy, where she effectively translates research findings into practical solutions for public health challenges. Her work consistently reflects a high level of analytical rigor and a commitment to advancing public health outcomes.

Awards and Recognition

Maryam has received several certificates of participation and training, including the Training of Trainers certificates, a peer reviewer course, and various certificates in statistical analysis and genetic research. These accolades demonstrate her commitment to continuous learning and professional development.

Conclusion

Maryam Qasim is a promising candidate for the Best Researcher Award due to her significant contributions to antimicrobial resistance research and molecular genetics. Her work, although primarily regional, has the potential to address broader health issues through applied research and collaborative efforts. Her academic background and continued professional development through various certifications further strengthen her candidacy.

Publications Top Notes

  1. Progress Toward the Elimination of Hepatitis B and Hepatitis C in the Country of Georgia, April 2015-April 2024
    • Authors: Tohme, R.A., Shadaker, S., Adamia, E., Schumacher, I.T., Gabunia, T.
    • Year: 2024
  2. Piloting a Simplified Bio-Behavioural Survey Methodology, the BBS-Lite, Among People Who Inject Drugs in Georgia
    • Authors: Gogia, M., Ruadze, E., Kasrashvili, T., Khonelidze, I., Stvilia, K.
    • Year: 2024
  3. Recommendations for Defining Preventable HIV-Related Mortality for Public Health Monitoring in the Era of Getting to Zero: An Expert Consensus
    • Authors: Croxford, S.E., Martin, V., Lucas, S.B., Waters, L.J., Sullivan, A.K.
    • Year: 2023
    • Citations: 1
  4. Barriers of Linkage to HCV Viremia Testing Among People Who Inject Drugs in Georgia
    • Authors: Butsashvili, M., Abzianidze, T., Kamkamidze, G., Nasrullah, M., Averhoff, F.
    • Year: 2022
    • Citations: 2
  5. Hidden Populations: Risk Behaviours in Drug-Using Populations in the Republic of Georgia Through Subsequent Peer-Driven Interventions
    • Authors: Lawlor, C., Gogia, M., Kirtadze, I., Jikia, G., Zurashvili, T.
    • Year: 2021
    • Citations: 1
  6. A Global Survey on Changes in the Supply, Price, and Use of Illicit Drugs and Alcohol, and Related Complications During the 2020 COVID-19 Pandemic
    • Authors: Farhoudian, A., Radfar, S.R., Ardabili, H.M., Yitayih, Y., Zhao, M.
    • Year: 2021
    • Citations: 44
  7. Reorganization of Substance Use Treatment and Harm Reduction Services During the COVID-19 Pandemic: A Global Survey
    • Authors: Radfar, S.R., De Jong, C.A.J., Farhoudian, A., Zhao, M., Zonoozi, A.K.
    • Year: 2021
    • Citations: 53
  8. Integration of Hepatitis C Treatment at Harm Reduction Centers in Georgia—Findings from a Patient Satisfaction Survey
    • Authors: Butsashvili, M., Kamkamidze, G., Kajaia, M., Japaridze, M., Averhoff, F.
    • Year: 2020
    • Citations: 9
  9. Progress in Testing for and Treatment of Hepatitis C Virus Infection Among Persons Who Inject Drugs — Georgia, 2018
    • Authors: Stvilia, K., Spradling, P.R., Asatiani, A., Averhoff, F., Nasrullah, M.
    • Year: 2019
    • Citations: 17
  10. Hidden Populations: Discovering the Differences Between the Known and the Unknown Drug-Using Populations in the Republic of Georgia
    • Authors: Gogia, M., Lawlor, C., Shengelia, N., Stvilia, K., Raymond, H.F.
    • Year: 2019
    • Citations: 1

 

Claudia Von Arx | Medicine and Dentistry | Best Researcher Award

Dr. Claudia Von Arx | Medicine and Dentistry | Best Researcher Award

Oncology consultant/Researcher of INT IRCCS Fondazione G. Pascale, Italy.

Claudia Von Arx is a dedicated researcher and medical professional with a wealth of experience in oncology research. She completed her medical degree at the University of Naples “Federico II” and subsequently specialized in Medical Oncology. Claudia pursued her passion for research by undertaking a PhD at Imperial College London, focusing on the development of recombinant OPCML tumor suppressor protein as a therapy for ovarian cancer. With extensive experience as a clinical research fellow at prestigious institutions like Imperial College London and INT IRCSS Fondazione G. Pascale of Naples, Claudia has contributed significantly to preclinical and translational research in oncology. Her expertise lies in developing predictive biomarkers, planning and conducting clinical trials, and exploring innovative treatment strategies for various types of cancer. Claudia’s commitment to advancing cancer research and patient care underscores her dedication to improving outcomes in oncology.

Professional Profiles:

Education

Ali Gholizadeh pursued his academic journey with distinction, attaining a Master of Science (2) in Material and Surface Engineering from École Nationale Supérieure d’Arts et Métiers (ENSAM) in 2020. Prior to this, he completed a Master of Science (1) in Mechanical Engineering, with a focus on Fluid Dynamics, also from ENSAM, in 2018. Ali’s educational foundation was laid with a Bachelor of Science in Mechanical Engineering from Shahid Bahonar University of Kerman in 2017. Throughout his academic career, Ali demonstrated exceptional aptitude and dedication, evidenced by his research projects and academic achievements.

Professional Experience

Ali Gholizadeh is an accomplished engineer with a diverse background in research and development. Currently serving as a Research Engineer at the University of Liège, he specializes in the development of innovative chip architectures for biochemical workflows. With previous roles at Fluigent and the Science and Technology Research Center, Ali has honed his skills in microfluidic technologies, CAD design, and data analysis. His academic journey includes a Master’s degree in Material and Surface Engineering from École Nationale Supérieure d’Arts et Métiers and a Bachelor’s degree in Mechanical Engineering from Shahid Bahonar University of Kerman. Throughout his career, Ali has demonstrated a strong commitment to advancing engineering solutions through cutting-edge research and development initiatives.

Research Interest

Ali Gholizadeh’s research interests encompass several areas of engineering, with a primary focus on microfluidic technologies and their applications. He is particularly interested in the design and optimization of microfluidic chips for various biochemical workflows, including sample preparation, analysis, and diagnostics. Additionally, Ali is passionate about exploring novel materials and fabrication techniques to enhance the performance and functionality of microfluidic devices. His research also extends to areas such as lab-on-a-chip systems, high-speed imaging, and instrument interface development. Overall, Ali’s goal is to contribute to the advancement of interdisciplinary research at the intersection of engineering, biology, and medicine, with the ultimate aim of addressing real-world challenges and improving human health.

Award and Honors

Ali Gholizadeh has received several honors and awards in recognition of his contributions to research and academia. Notably, he was selected as a ranked student for participation in a prestigious dual degree program between IUST and ENSAM, where his master’s project received the highest score by the jury. Additionally, he achieved the top 1% rank among 35,000 participants in the nationwide university entrance exam for graduate studies in Mechanical Engineering, earning a full scholarship to study at IUST. These accomplishments highlight Ali’s academic excellence and dedication to his field, positioning him as a promising young researcher in the engineering community.

Research Skills

Ali Gholizadeh possesses a diverse set of research skills that enable him to excel in his field. His expertise includes design and microfabrication of electromechanical instruments and microfluidic chips, along with proficiency in CAD, 3D printing, and software programming for development purposes. He is skilled in data analysis and post-processing, utilizing tools such as MATLAB, Python, and image processing techniques. Additionally, Ali has experience in high-speed imaging and microscopy, contributing to his ability to conduct detailed analysis and observation in his research projects. His critical thinking, problem-solving abilities, and strong teamwork skills further enhance his research capabilities, allowing him to make significant contributions to the advancement of engineering and technology.

Publications

  1. A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial
    • Authors: C. von Arx, G. Della Vittoria Scarpati, L. Cannella, A. Ottaiano, S. Tafuto
    • Journal: ESMO Open
    • Year: 2024
    • Volume: 9
    • Issue: 5
    • Citations: 0
  2. Cancer genetic counselling for hereditary breast cancer in the era of precision oncology
    • Authors: M. Pensabene, A. Calabrese, C. von Arx, R. Caputo, M. De Laurentiis
    • Journal: Cancer Treatment Reviews
    • Year: 2024
    • Volume: 125
    • Citations: 0
  3. Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion
    • Authors: R. Caputo, G. Buono, V.D. Lauro, F. Nuzzo, M. De Laurentiis
    • Journal: Future Oncology
    • Year: 2023
    • Volume: 19
    • Issue: 24
    • Pages: 1695–1708
    • Citations: 0
  4. The Complex Management of the Breast Angiosarcoma: A Retrospective Study
    • Authors: L. Cannella, F. Perri, O. Clemente, A. De Chiara, S. Tafuto
    • Journal: Oncology (Switzerland)
    • Year: 2023
    • Volume: 101
    • Issue: 4
    • Pages: 234–239
    • Citations: 1
  5. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer
    • Authors: C. von Arx, P. De Placido, A. Caltavituro, M. Giuliano, L. Del Mastro
    • Journal: Cancer Treatment Reviews
    • Year: 2023
    • Volume: 113
    • Citations: 17
  6. Male Breast Cancer: From Molecular Genetics to Clinical Management
    • Authors: M. Pensabene, C. Von Arx, M. De Laurentiis
    • Journal: Cancers
    • Year: 2022
    • Volume: 14
    • Issue: 8
    • Pages: 2006
    • Citations: 10
  7. Editorial: The Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer: Challenges and Perspectives
    • Authors: A. Ottaiano, M. Berretta, C. Von Arx, M. Capozzi, M. Caraglia
    • Journal: Frontiers in Oncology
    • Year: 2022
    • Volume: 12
    • Pages: 852445
    • Citations: 1
  8. Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest)
    • Authors: I.M. Modlin, M. Kidd, K. Oberg, I.A. Drozdov, A. Kitz
    • Journal: Annals of Surgical Oncology
    • Year: 2021
    • Volume: 28
    • Issue: 12
    • Pages: 7506–7517
    • Citations: 24
  9. Selinexor and the selective inhibition of nuclear export: A new perspective on the treatment of sarcomas and other solid and non-solid tumors
    • Authors: A.L. Marretta, G. Di Lorenzo, D. Ribera, A. Pizzolorusso, S. Tafuto
    • Journal: Pharmaceutics
    • Year: 2021
    • Volume: 13
    • Issue: 9
    • Pages: 1522
    • Citations: 2
  10. Uptake of trastuzumab biosimilars for the treatment of HER2-positive breast cancer: A real-world experience from a cancer center
    • Authors: M. Piezzo, R. D’aniello, I. Avallone, M. De Laurentiis, P. Maiolino
    • Journal: Pharmaceutics
    • Year: 2021
    • Volume: 13
    • Issue: 5
    • Pages: 684
    • Citations: 3